Category Archives: HIV care & treatment

HIV advocates publish HIV/AIDS Cure Research Glossary & Resource Guide

HIVCureGlossary

  To better inform journalists, service workers, advocates and people with HIV on the exciting and rapidly moving field of HIV cure research, advocates from the Delaney AIDS Research Enterprise (DARE), with assistance from advocates from the defeatHIV collaboratory and the Collaboratory of AIDS Researchers for…Read More

A Plan to End California’s HIV/AIDS Epidemic is Developing

g2zero

In our March issue of PIPeNews, we reported that Project Inform has been heavily involved in the development and implementation of San Francisco’s Getting to Zero strategy for eliminating HIV related deaths and new infections.  This work follows, of course, from our significant participation in calling…Read More

CROI 2016: Switching to regimen with new form of tenofovir (TAF) improves kidney and bone health markers

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, 96-week results were presented from a phase 3 study that switched individuals from a regimen with the older version of tenofovir (tenofovir disoproxil fumarate, TDF) to a newer version (tenofovir alafenamide, TAF) to compare…Read More

CROI 2016: Early results show doravirine regimen as effective as efavirenz regimen

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, early 48-week results showed that the experimental NNRTI doravirine suppressed HIV levels as well as efavirenz (Sustiva) but with lower rates of side effects. No NNRTIs are currently listed as a “recommended” starting regimen…Read More

CROI 2016: New attachment inhibitor showing promise for treatment experienced patients

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, 96-week results were reported on from a Phase II study of BMS-663068 — a new class of drugs called attachment inhibitors. This type of drug works by attaching itself onto HIV’s receptor called gp120,…Read More

CROI 2016: Maintenance regimen of injected cabotegravir + rilpivirine advances through study

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, early results from the LATTE-2 study were presented on a maintenance regimen of cabotegravir + rilpivirine given by injection every 4 or 8 weeks. Cabotegravir is an experimental integrase inhibitor while the oral version…Read More

CROI 2016: Promising results for new, simpler dosing of raltegravir (Isentress)

croi2016sm

Although not presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, a press release was released near the start of CROI about a phase 3 study of the integrase inhibitor, raltegravir (Isentress). The study, called ONCEMRK, compared a new once-a-day dosing of…Read More